The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.
This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.
Yves Dauvilliers,1 Ronald R. Grunstein,2,3 Emmanuel Mignot,4 Gert J. Lammers,5,6 David T. Plante,7 Erik Buntinx,8 Rafael del Río Víllegas,9,10 Hailu Chen,11 Craig Hopkinson,11 Bhaskar Rege,11 Julie Himes,11 Michael J. Doane,11 Giuseppe Plazzi12,13
1Sleep–Wake Disorders Centre, Department of Neurology, Gui de Chauliac Hospital, Montpellier, University of Montpellier, INSERM Institute for Neurosciences of Montpellier, Montpellier, France; 2Woolcock Institute of Medical Research, Macquarie University; 3Sydney Health Partners, The University of Sydney, Sydney, Australia; 4Stanford Center for Narcolepsy and Hypersomnia, Stanford University School of Medicine, Stanford, CA, United States; 5Leiden University Medical Center, Leiden, Netherlands; 6Stichting Epilepsie Instellingen Nederland, Sleep-Wake Centre, Heemstede, Netherlands; 7University of Wisconsin-Madison, School of Medicine and Public Health, Madison, WI, United States; 8ANIMA Research, Alken, Belgium; 9Neurophysiology and Sleep Disorders Unit, Vithas Madrid Hospitals, Madrid, Spain; 10Departamento de Ciencias Médicas Clínicas Universidad CEU San Pablo, CEU Universities, Vithas Madrid Hospitals, Madrid, Spain; 11Alkermes, Inc., Waltham, MA, United States; 12IRCCS Istituto delle Scienze Neurologiche; 13University of Modena and Reggio-Emilia, Modena, Italy
